Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

ADSC therapy in neurodegenerative disorders.

Chan TM., Chen JY., Ho LI., Lin HP., Hsueh KW., Liu DD.

Clinical Trial on Neuroinflammation, published in Cell Transplant (2014) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Cell Transplant (2014)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
24816450
DOI
10.3727/096368914X678445
Citations
38

Abstract (original English)

Neurodegenerative disorders, chronic diseases that can severely affect the patient's daily life, include amyotrophic lateral sclerosis, Parkinson's, Alzheimer's, and Huntington's diseases. However, these diseases all have the common characteristic that they are due to degenerative irreversibility, and thus no efficient drugs or therapy methods can mitigate symptoms completely. Stem cell therapy, such as adipose tissue-derived stem cells (ADSCs), is a promising treatment for incurable disorders. In this review, we summarized the previous studies using ADSCs to treat neurodegenerative disorders, as well as their therapeutic mechanisms. We also suggested possible expectations for future human clinical trials involving minimized intracerebroventricular combined with intravenous administration, using different cell lineages to finish complementary therapy as well as change the extracellular matrix to create a homing niche. Depending on successful experiments in relevant neurodegenerative disorders models, this could form the theoretical basis for future human clinical trials.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueAlzheimer DiseaseAmyotrophic Lateral SclerosisAnimalsCell DifferentiationCell LineageHumansHuntington DiseaseNeurodegenerative DiseasesParkinson Disease

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research